BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:efpeglenatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of efpeglenatide\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07379333-230@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:efpeglenatide: Phase 3 readout est. (NCT07379333)
DESCRIPTION:efpeglenatide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to E
 valuate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes M
 ellitus Inadequately Controlled With Metformin and Dapagliflozin\nEstimate
 d primary completion: November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/efpeglenatide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07379333
URL:https://assetmemo.bio/drug/efpeglenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
